Phase 3 N=130 Corneal Collagen Cross-Linking for Ectasia (CXL)
Ectasia
Primary: Mean Change From Baseline in Maximum Keratometry (Kmax) — -0.5; 0.5 diopters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=60 Evaluation of Coronary Luminal Diameter Enlargement With Emerge™ 1.20 mm PTCA Dilatation Catheter
Coronary Artery Disease
Primary: Device Procedural Success — 98.3 percentage of participants
Phase 2 N=510 Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia
Keratoconus · Post-Refractive Ectasia
Primary: Change in Maximum Keratometry From Baseline to 6 Months After Treatment — 0.76; 0.97 diopters
N/A N=21 Early Experience With Descemet's Stripping Automated Endothelial Keratoplasty
Corneal Edema Secondary to Corneal Endothelial Dystrophy
Primary: Best Spectacle Corrected Visual Acuity (BSCVA) — 1; 3; 7; 9 Participants
N/A N=37 Endothelial Bleb Response With Toric Lenses
Ametropia
Primary: Endothelial Bleb Areas on Cornea: Session A- Open Eye — 0.1; 2.0; 0.2; 2.1 Percent Difference of Bleb Area
N/A N=25 "EASE" Epicardial Access With the EpiAccess System
Arrhythmias, Cardiac
Primary: Percentage of Participants in Whom Pericardial Access Was Achieved With the EpiAccess System — 100 percentage of patients
N/A N=60 XprESS Eustachian Tube Dilation Study
Eustachian Tube Dysfunction
Primary: Change From Baseline in Mean Overall ETDQ-7 Scores — -2.9; -0.6 units on a scale — p=<0.0001
N/A N=7 Evaluation of Pancreatobiliary Disorders in Patients With Altered Gastric Anatomy
Pancreatobiliary Disease · Altered Gastric Anatomy
Primary: Papilla or Duct-enterostomy Was Reached — 10 ERCPs
N/A N=323 Study of Safety and Efficacy for the Eustachian Tube Balloon Catheter
Eustachian Tube Dysfunction
Primary: Primary Efficacy Analysis: Number of Randomized Subjects With Tympanogram Normalization at 6 Weeks — 73; 10 Participants
N/A N=213 Tack Optimized Balloon Angioplasty Study of the Tack Endovascular System™ in Femoropoliteal Arteries
Peripheral Artery Disease
Primary: Efficacy - Number of Subjects That Met Primary Patency Criteria at 12 Months — 120 Participants
N/A N=19 34mm Cuff Study for Endovascular Repair of Abdominal Aortic Aneurysms
Abdominal Aortic Aneurysm
Primary: Number of Participants With Proximal Type I Endoleak at Each Timepoint — 1; 0; 0; 0 Participants
Phase 2 N=261 Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial
Aneurysm
Primary: Difference in Z-score for Rank of Maximum Transverse Diameter (MTD) Regressed on Z-score at Baseline to Assess Growth in Abdominal Aortic Aneurysm MTD Determined by CT…
N/A N=50 Evaluation of the GORE Conformable TAG® Thoracic Endoprosthesis for Treatment of Acute Complicated Type B Aortic Dissection
Type B Aortic Dissection
Primary: All-cause Mortality Incidence Through 30 Days Post-treatment — 5 participants — p=.006
N/A N=233 Tack Optimized Balloon Angioplasty Study of the Tack Endovascular System® in Below the Knee Arteries
Peripheral Arterial Disease
Primary: Efficacy - Number of Participants With Freedom From MALE at 6 Months and POD at 30 Days — 200 Participants
N/A N=44 Suprarenal Proximal Cuff Study for Treatment of Abdominal Aortic Aneurysm
Abdominal Aortic Aneurysm
Primary: Number of Subjects With Proximal Type I Endoleak — 2 Participants
N/A N=20 Endovascular Repair for the Descending Thoracic Aorta
Aorta Thoracic; Traumatic Rupture
Primary: Number of Participants With Major Adverse Events — 0 number of serious adverse events
Phase 3 N=1 Lucentis (Ranibizumab) for Eales' Disease
Eales' Disease
Primary: Change in OCT Thickness. — 269; 262 um